inflammatory and immunomodulatory properties [1, 2] . These properties have recently been studied in two different murine models of autoimmunity: one of experimental autoimmune encephalomyelitis [3] and one of collagen-induced arthritis [4] . Atorvastatin and simvastatin significantly suppressed autoimmunity in these respective animal models by inhibiting pathological pro-inflammatory responses. In both cases, evidence was found of a shift from a T helper type 1 (Th1) to a Th2 cell response [3, 4] . There is also evidence that atorvastatin can mediate a modest, but clinically apparent, anti-inflammatory effect in patients with rheumatoid arthritis [5] .
The development of type 1 diabetes needs to be prevented. Previous studies have shown that 1α,25-dihydroxyvitamin D 3 or nicotine treatments in mice arrested the progression of type 1 diabetes with a concomitant, potentially related inhibition of Th1 CD4 + T cell infiltration of the pancreas [6, 7] . To gain preliminary insight into the potential usefulness of statins in patients with prediabetes, we sought to determine whether atorvastatin could delay, or even prevent, diabetes onset in two experimental models of type 1 diabetes: multiple low-dose streptozotocin and spontaneous non-obese diabetic (NOD) mice.
Female NOD mice were purchased from Taconic (Bomholt, Denmark) and maintained under pathogen-free conditions, and 4-to 5-week-old C57BL/6 male mice were purchased from Charles River Laboratories (Santa Perpè-tua de la Mogoda, Spain). The mice were fed an irradiated and non-irradiated regular chow diet (Harlan Ibérica, Sant Feliu de Codines, Spain), respectively, with or without 0.01% (w/w) atorvastatin (Zarator; Pfizer, Madrid, Spain), equivalent to an approximate daily dose of 10 mg of atorvastatin per kg of body weight. Diabetes was induced in the C57BL/6 mice by i.p. injection of 60 mg/kg streptozotocin in citrate buffer, pH 4.5, for 5 consecutive days. In a separate experiment, atorvastatin was suspended in phosphate buffer and administered once daily by i.p. injection to streptozotocin-treated mice at a dose of 20 mg/kg. Nonfasting blood glucose was monitored weekly and diabetes was diagnosed when glucose levels exceeded 11.1 mmol/l in two consecutive tests.
Atorvastatin did not significantly reduce the incidence of diabetes or delay its onset, despite the different models, doses and administration routes tested. Neither the oral nor the i.p. atorvastatin treatment reduced the incidence or severity of diabetes in streptozotocin-induced mice, as indicated by the kinetics of hyperglycaemia development (Fig. 1a, b) . Atorvastatin also failed to prevent diabetes development in NOD mice (Fig. 1c) . In the NOD mice, the first case of overt diabetes was seen at week 12 in the atorvastatin-treated group and at week 14 in the control group. The disease rate increased continuously thereafter up to 78 and 59% (p=0.17), respectively, by week 40.
Our data are consistent with those obtained by Kanda et al. [8] who reported a slight, but significantly worse, glucose tolerance in streptozotocin-induced diabetic rats treated with atorvastatin or pravastatin.
The lack of effect of atorvastatin in the present study could be explained by the low dose used. Some authors argue that achievement of pleiotropic effects in mice may require a dose of up to 40 mg·kg −1 ·day −1 [4] . These doses are much higher than those used in man, but could be necessary in murine studies as a result of the rapid upregulation of HMG-CoA reductase in response to the treatment [4] . However, it has been reported that the minimum dose required to induce an immunomodulatory effect in murine experimental autoimmune encephalomyelitis is 0.1 mg/kg, which is clearly below the dose administered in our mice [3] .
An effect of food intake cannot be ruled out either, since food ingestion decreases the bioavailability of fluvastatin, pravastatin and atorvastatin in humans [9] , although plasma atorvastatin concentrations were not measured in our treated mice. However, no differences existed in food intake between the groups of animals being compared; furthermore, i.p. injections of atorvastatin were also unable to prevent diabetes in streptozotocin-treated mice.
The administration period for atorvastatin was comparable to that for other immunomodulatory treatments, such as 1α,25dihydroxyvitamin D 3 and nicotine, which have previously been reported to ameliorate or reduce diabetes incidence in mice [6, 7] , thus ruling out the possibility of an insufficient period of treatment.
Other types of effects of statins on diabetes are also possible. Pravastatin reduced the risk of the development of type 2 diabetes by 30% in the West of Scotland Coronary Prevention Study (WOSCOPS) [4] . This effect could have been caused by a statin-induced decrease in plasma triglyceride, oxidative stress and inflammation in these patients [10, 11] . However, we believe that, at this point in time, the potential effect of statins on type 2 diabetes prevention could be better addressed by clinical studies than by animal experimentation.
In conclusion, we were unable to substantiate any protective effect of atorvastatin, administered orally or i.p., on diabetes development in mouse models of type 1 diabetes.
